Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 36, Issue 1, 2012, Pages 71-77

  Gassó, Patricia ^a,c,d   Mas, Sergi ^a,c,d   Molina, Oriol ^b   Bernardo, Miquel ^a,b,c,d   Lafuente, Amalia ^a,c,d   Parellada, Eduard ^a,b,c,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Antipsychotic; Extrapyramidalism; Neuroblastoma; Neuroprotection; Neurotoxicity

Indexed keywords

CASPASE 3; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; PALIPERIDONE; RISPERIDONE;

ARTICLE; BINDING AFFINITY; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMAN CELL; MONOTHERAPY; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY;

CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HALOPERIDOL; HUMANS; ISOXAZOLES; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; PYRIMIDINES; RISPERIDONE;

EID: 82555190988     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.08.010     Document Type: Article

References (40)

1. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988, 1:179-186.
2. Carpenter W.T., Buchanan R.W. Schizophrenia. N Engl J Med 1994, 330:681-690.
3. Chen D.F., Schneider G.E., Martinou J.C., Tonegawa S. Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature 1997, 385:434-439.
4. Chiueh C.C., Miyake H., Peng M.T. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol 1993, 60:251-258.
5. Crescenti A., Mas S., Gassó P., Parellada E., Bernardo M., Lafuente A. CYP2D6 *3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side effects in patients receiving antipsychotic therapy. Clin Exp Pharmacol Physiol 2008, 35:807-811.
6. Dayalu P., Chou K.L. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 2008, 9:1451-1462.
7. Farde L., Nordström A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992, 49:538-544.
8. Galili R., Gil-Ad I., Weizman A., Melamed E., Offen D. Haloperidol-induced neurotoxicity-possible implications for tardive dyskinesia. J Neural Transm 2000, 107:479-490.
9. Gassó P., Mas S., Bernardo M., Álvarez S., Parellada E., Lafuente A. A common variant in DRD3 gene is associated with antipsychotic induced extrapyramidal symptoms. Pharmacogenomics J 2009, 9:404-410.
10. Gassó P., Mas S., Crescenti A., Parramon G., Garcia-Rizo C., Parellada E., et al. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. Psychiatr Res 2010, 175:173-175.
11. Gassó P., Mas S., Oliveira C., Bioque M., Parellada E., Bernardo M., et al. Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients. Eur Neuropsychopharmacol 2011, 21:294-299.
12. Gil-ad I., Shtaif B., Shiloh R., Weizman A. Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms. Cell Mol Neurobiol 2001, 21:705-716.
13. Greenbaum L., Smith R.C., Rigbi A., Strous R., Teltsh O., Kanyas K., et al. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region. Pharmacogenomics J 2009, 9:103-110.
14. Han J.M., Lee Y.J., Lee S.Y., Kim E.M., Moon Y., Kim H.W., et al. Protective effect of sulforaphane against dopaminergic cell death. J Pharmacol Exp Ther 2007, 321:249-256.
15. Kang U.G., Seo M.S., Roh M.S., Kim Y., Yoon S.C., Kim Y.S. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett 2004, 560:115-119.
16. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000, 157:514-520.
17. Kim N.R., Park S.W., Lee J.G., Kim Y.H. Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:633-642.
18. Lafuente A., Bernardo M., Mas S., Crescenti A., Aparici M., Gassó P., et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res 2007, 90:115-122.
19. Lafuente A., Bernardo M., Mas S., Crescenti A., Aparici M., Gassó P., et al. Polymorphism of Dopamine D2 receptor (TaqIA, TaqIB, and -141C Ins/Del) and Dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatr Res 2008, 161:131-141.
20. Lennon S.V., Martin S.J., Cotter T.G. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 1991, 24:203-214.
21. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 1998, 43:596-604.
22. Lieberman J.A., Bymaster F.P., Meltzer H.Y., Deutch A.Y., Duncan G.E., Marx C.E., et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008, 60:358-403.
23. Liou Y.J., Wang Y.C., Chen J.Y., Bai Y.M., Lin C.C., Liao D.L., et al. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res 2007, 153:271-275.
24. Mas S., Gassó P., Alvarez S., Parellada E., Bernardo M., Lafuente A. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 2010, 10.1038/tpj.2010.91.
25. McDonagh M., Peterson K., Carson S., Fu R., Thakurta S. Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report 2010, Oregon Health & Science University.
26. McIntyre R.S., Konarski J.Z. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorders. J Clin Psychiatry 2005, 66:28-36.
27. Meltzer H., Massey B. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011, 11:59-67.
28. Molteni R., Calabrese F., Racagni G., Fumagalli F., Riva M.A. Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 2009, 124:74-85.
29. Noh J.S., Kang H.J., Kim E.Y., Sohn S., Chung Y.K., Kim S.U., et al. Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH(2)-terminal protein kinase. J Neurochem 2000, 75:2327-2334.
30. Offen D., Ziv I., Gorodin S., Barzilai A., Malik Z., Melamed E. Dopamine-induced programmed cell death in mouse thymocytes. Biochim Biophys Acta 1995, 1268:171-177.
31. Qing H., Xu H., Wei Z., Gibson K., Li X.M. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci 2003, 17:1563-1570.
32. Remington G., Kapur S. D2 and 5HT2 receptor effects of antipsychotic; bridging basic and clinical findings using PET. J Clin Psychiatry 1999, 60:15-19.
33. Ukai W., Ozawa H., Tateno M., Hashimoto E., Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm 2004, 111:667-681.
34. Wei Z., Bai O., Richardson J.S., Mousseau D.D., Li X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res 2003, 73:364-368.
35. Wei Z., Mousseau D.D., Richardson J.S., Dyck L.E., Li X.M. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization. J Neurosci Res 2003, 74:942-947.
36. Xu M.Q., Xing Q.H., Zheng Y.L., Li S., Gao J.J., He G., et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry 2007, 68:1358-1367.
37. Xu M.Q., St Clair D., Feng G.Y., Lin Z.G., He G., Li X., et al. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet Genomics 2008, 18:449-457.
38. Yang B.H., Son H., Kim S.H., Nam J.H., Choi J.H., Lee J.S. Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration. Psychiatry Clin Neurosci 2004, 58:262-267.
39. Zhuravliova E., Barbakadze T., Natsvlishvili N., Mikeladze D.G. Haloperidol induces neurotoxicity by the NMDA receptor downstream signalling pathway, alternative from glutamate excitotoxicity. Neurochem Int 2007, 50:976-982.
40. Ziv I., Melamed E., Nardi N., Luria D., Achiron A., Offen D., et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons-a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 1994, 170:136-140.